Radcliffe Medical Education is hosting a symposium entitled 'The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM' at 12:30 UCT+1 on Sunday 1 September 2024 in the Prague Room at ESC 2024, ExCel Centre, London, UK.

Overview

Prof Julian Gillmore (University College London, London, UK) will lead a distinguished faculty in an upcoming CME-accredited session. The faculty includes Dr Ahmad Masri (Oregon Health & Science University Medical Group, Portland, US), Dr Margot Davis (University of British Columbia, Vancouver, CA), and Dr Giuseppe Vergaro (Sant’Anna, Pisa, IT). They will present recent epidemiological data on ATTR-CM incidence and diagnostic trends. The session will teach the audience how to identify patients who should undergo detailed diagnosis and list the red flags indicating ATTR amyloidosis. Don't miss this opportunity to enhance your diagnostic skills in ATTR-CM.

Programme – The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM

• Introduction.
• A contemporary view of ATTR-CM epidemiology
• Practical screening: What's the role of the cardiologist?
• Where are we now and what's next in medical management?
• Chair's closing remarks and audience questions. 
  
   

Learning Objectives 

• Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends.
• List red flags indicating the presence of ATTR amyloidosis .
• Identify patients who should undergo detailed diagnosis work-up or referral.
• List the advantages of emerging classes of agents being evaluated in ATTR-CM.

For further details on the programme, visit ESC 2024.

The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM’s programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME credit, equating to 1 hour of effective education time. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

This activity is supported by an unrestricted educational grant from AstraZeneca. AstraZeneca has had no involvement in the selection of the speakers, the development of the activity, the agenda or the materials.